Movement Disorders Fellowship Program at Toronto Western Hospital
Through the support of the Porridge for Parkinson’s 2019 event, the Movement Disorders Fellowship Program at Toronto Western Hospital has provided two Fellows with a unique opportunity to receive superb education, mentorship and clinical experiences through video meetings, research rounds and journal clubs. Dr. Daniel Garbin Di Luca and Dr. Diana Olszewska are able to continue their research to become experts in their field, and collaborate with movement disorders clinicians and research leaders to ultimately provide patients with the best clinical care possible.
Dr. Garbin Di Luca
Dr. Garbin Di Luca is a Movement Disorders Fellow at Toronto Western Hospital. He completed his neurology residency at the University of Miami, where he also served as a chief resident. Dr Di Luca also completed a fellowship at Massachusetts General Hospital/Harvard Medical School where he investigated the role of caffeine and adenosine in Parkinson’s disease. In his Fellowship at Toronto Western Hospital, Dr. Di Luca is currently evaluating the clinical phenotype of patients with LRRK2 mutations and studying interventions to treat non-motor manifestations. His other research interests include deep brain stimulation, epidemiology, health disparities and clinical trials in movement disorders.
Dr. Diana Olszewska
Dr. Diana Olszewska obtained her MD at the Medical University of Warsaw, her neurology training program at the Royal College of Physicians of Ireland, and her PhD at the University College Dublin. Her PhD focused on studying genetics and skin biomarkers of Parkinson’s disease. Dr. Olszewska led the development of the first adult neuro-genetic clinic in Ireland. She continued this work in genetics at the Mayo Clinic in Jacksonville, Florida. Dr. Olszewska is a Movement Disorders Fellow at Toronto Western Hospital, involved in the Movement Disorders Clinic and the Botulinum Toxin Clinic. Her research is focused on developing biomarkers in various bio-fluids using novel techniques and expanding her investigations of genotype-phenotype correlations in movement disorders and the role of therapeutics. Dr. Olszewska’s goals are to excel in patient care, stimulate innovation, and work towards the development of a diagnostic test and a disease-modifying therapy for Parkinson’s disease.
